News & Events

Tarix Pharmaceuticals’ TXA127 Granted Orphan Drug Status for Treatment of Pulmonary Arterial Hypertension

By Tarix Pharma | Published: September 27, 2011

September 27, 2011

Posted in News & Events | Comments closed

Tarix Pharmaceuticals Enrolls First Patient in Phase 1 Clinical Study of TXA127 in Adult Patients Following Double Cord Blood Stem Cell Transplant

By Tarix Pharma | Published: April 26, 2011

April 26, 2011

Posted in News & Events | Comments closed

Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant

By Tarix Pharma | Published: February 23, 2011

February 23, 2011

Posted in News & Events | Comments closed

Tarix Pharmaceuticals’ TXA127 Receives FDA Orphan Drug Designation for Stem Cell Engraftment

By Tarix Pharma | Published: June 28, 2010

June 28, 2010

Posted in News & Events | Comments closed

University of Southern California receives additional grant to study TXA127 for the prevention of radiation damage

By Tarix Pharma | Published: March 22, 2010

March 22, 2010

Posted in News & Events | Comments closed

Tarix Pharmaceuticals receives FDA approval to initiate a Phase II trial to enhance engraftment in peripheral blood stem cell transplantation

By Tarix Pharma | Published: December 3, 2009

December 3, 2009

Posted in News & Events | Comments closed

Tarix Pharmaceuticals announces the first patient recruited into its Phase 2 study to mitigate chemotherapy-induced thrombocytopenia

By Tarix Pharma | Published: February 19, 2009

February 19, 2009

Posted in News & Events | Comments closed

Tarix Pharmaceuticals recruits first patient in clinical trial to treat HIV patients with persistently low CD4 counts

By Tarix Pharma | Published: November 12, 2008

November 12, 2008

Posted in News & Events | Comments closed

University of Southern California receives $1 million NIH grant to study TXA127 for the prevention of radiation damage

By Tarix Pharma | Published: November 7, 2008

November 7, 2008

Posted in News & Events | Comments closed

Tarix Pharmaceuticals receives FDA approval for Phase 2 study to mitigate chemotherapy-induced thrombocytopenia

By Tarix Pharma | Published: June 25, 2008

June 25, 2008

Posted in News & Events | Comments closed

Tarix Pharmaceuticals receives IND to treat HIV patients with persistently low CD4 counts

By Tarix Pharma | Published: March 21, 2008

March 21, 2008

Posted in News & Events | Comments closed

Tarix Pharmaceuticals licenses peptide technology from University of Southern California

By Tarix Pharma | Published: May 20, 2007

May 20, 2007

Posted in News & Events | Comments closed